Mounjaro vs. Saxenda

See how Mounjaro and Saxenda compare on approved uses, dosing, side effects, and cost.

Key Takeaways

  • Mounjaro is FDA-approved for type 2 diabetes and used off-label for weight loss, while Saxenda is FDA-approved specifically for chronic weight management in adults and teens.

  • Mounjaro is injected once a week; Saxenda requires a daily injection with a four-week titration before reaching its single maintenance dose.

  • Both carry a boxed warning for thyroid C-cell tumors, but Saxenda's label adds warnings about increased heart rate and suicidal thoughts.

Mounjaro vs. Saxenda Drug Summary

Mounjaro

Mounjaro (tirzepatide) is a dual GIP/GLP-1 receptor agonist FDA-approved to control blood sugar in adults and children 10 and older with type 2 diabetes. It is injected once a week, with the dose slowly raised from 2.5 mg up to as much as 15 mg over about five months. Many prescribers also use it off-label for weight loss.

Saxenda

Saxenda (liraglutide) is a GLP-1 receptor agonist FDA-approved for chronic weight management in adults with obesity or overweight plus a weight-related condition, and in teens 12 to 17 with obesity. It is injected once a day, with the dose raised weekly from 0.6 mg to a 3 mg maintenance dose over one month. It is not approved to treat diabetes.

Mounjaro vs. Saxenda Side Effects

Mounjaro

Most common
nausea (12-18%)
diarrhea (12-17%)
vomiting (5-9%)
decreased appetite (8-11%)

Saxenda

Most common
nausea (39.3%)
diarrhea (20.9%)
vomiting (15.7%)
constipation (19.4%)

Mounjaro vs. Saxenda Dosage

Mounjaro

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 2.5 mg once weekly Weeks 1-4
Maximum dose 15 mg once weekly Week 21 onward
Dose changes 5 increases Every 4 weeks

Saxenda

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 0.6 mg once daily Week 1
Maximum dose 3 mg once daily Week 5 onward
Dose changes 4 increases Every week

Mounjaro vs. Saxenda Indications

Mounjaro

Mounjaro's only FDA-approved use is blood sugar management in type 2 diabetes. Using it for weight loss in people without diabetes is off-label, though it's a common practice built on strong clinical trial results.

  • Blood sugar control in adults with type 2 diabetes

  • Blood sugar control in pediatric patients 10 years and older with type 2 diabetes

  • Off-label use for weight loss in people without diabetes

  • Not approved for type 1 diabetes

Saxenda

Saxenda's FDA approval is specifically for chronic weight management, not diabetes. It works for adults with obesity, or with overweight plus a weight-related condition like high blood pressure, and for teens ages 12 to 17 with obesity.

  • Chronic weight management in adults with obesity or overweight plus a weight-related condition

  • Chronic weight management in adolescents 12-17 with obesity

  • Not approved for type 1 or type 2 diabetes (that's Victoza)

  • Not approved for use during pregnancy

Mounjaro vs. Saxenda Pros and Cons

Mounjaro

Mounjaro's dual-hormone mechanism has shown strong results for both blood sugar and weight, and once-weekly dosing fits easily into most routines. Because it isn't FDA-approved for weight loss on its own, insurance coverage for that use can be inconvenient to secure.

Pros

  • Once-weekly injection instead of a daily shot

  • Dual GIP/GLP-1 mechanism, the first of its kind

  • FDA-approved specifically for blood sugar control in type 2 diabetes

  • Higher maximum dose (15 mg) gives more room to escalate if needed

Cons

  • Weight loss use is off-label, which can complicate insurance approval

  • Longer titration period, about five months to reach the top dose

  • Contraindicated in patients with severe gastroparesis

  • Newer to market, so less long-term real-world safety data

Saxenda

Saxenda has been on the market since 2014 and is FDA-approved specifically for weight management, including in teens, so coverage doesn't hinge on off-label use. It requires a daily injection, and its label carries extra warnings around heart rate and mood that Mounjaro's does not include.

Pros

  • FDA-approved specifically for weight loss, not an off-label use

  • Approved for adolescents 12-17 with obesity

  • Over a decade of real-world use and safety data since 2014

  • Reaches its maintenance dose in just five weeks

Cons

  • Requires a daily injection instead of a weekly one

  • Higher rates of nausea and diarrhea reported in trials

  • Added label warnings for increased heart rate and suicidal thoughts

  • Cannot be used for blood sugar control in diabetes (Victoza is the diabetes version)

Common Symptoms and Related Diseases You Can Explore

Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.